CS
VERV

Candriam SCA’s Verve Therapeutics VERV Stock Holding History

Candriam SCA’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-310,000
Closed -$4.12M – 729
2024
Q1 		$4.12M Hold
310,000
– – 0.03% 376
2023
Q4 		$4.32M Buy
+310,000
New +$3.84M 0.03% 348
2023
Q2 		– Sell
-25,547
Closed -$339K – 868
2023
Q1 		$339K Buy
+25,547
New +$500K ﹤0.01% 845

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Candriam SCA's VERV Position: Q2 2024 in Review

Candriam SCA sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 310,000 shares — an estimated $4.12M sold.

Candriam SCA first reported a position in VERV in Q1 2023 and held it in 3 quarters. The position peaked at $4.32M in Q4 2023. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • Candriam SCA reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 310,000 Verve Therapeutics shares in Q2 2024, an estimated $4.12M.
  • Candriam SCA first reported a position in Verve Therapeutics in Q1 2023 and held it in 3 quarters.
  • Candriam SCA's Verve Therapeutics position peaked at $4.32M in Q4 2023.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.